Private Equity Firm Offers Unusually High Amount For Singapore’s AsiaPharm
This article was originally published in PharmAsia News
Executive Summary
A private equity firm has offered to acquire Singapore's AsiaPharm for U.S. $252 million and take the company private. The move is seen as a way to allow the injectables maker to acquire companies in mainland China where authorities are overhauling the drug regulation system. AsiaPharm executives, who own more than 44 percent of their firm's stock, have agreed to the deal. Such private equity deals in Asia generally are valued at much less than the offer by MBK Partners for AsiaPharm, keeping mergers and acquisition attractive propositions. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.